Becton Dickinson's $12 billion acquisition of CareFusion is set to close tomorrow, after European anti-trust regulators approved the merger last week.
The $12.2 billion merger of Becton Dickinson (NYSE:BDX) and CareFusion (NYSE:CFN) is slated to close tomorrow, the companies said, after European anti-trust regulators last week approved the deal.
Franklin Lakes, N.J.-based Becton agreed last October to pay a total of $58.00 a share – $49.00 in cash and 0.0777 of a BDX share – for each CFN share, representing a premium of 26% to the closing price on Oct. 3.
The deal would unite 2 complementary product lines: BD makes products to deliver and administer drugs, such as disposable needles, syringes and intravenous catheters, while CareFusion makes products to store and deliver drugs, such as infusion pumps.
Anti-trust regulators in the U.S. approved the deal last November; the EU nod was the buyout's final regulatory hurdle, according to a regulatory filing, setting the stage for a closing tomorrow.